Olanzapine Mylan

Olanzapine, the active ingredient in Olanzapine Mylan, is an atypical antipsychotic presented as a tablet for oral use. It is used to manage symptoms of schizophrenia and bipolar disorder in adults.

GNH USA supplies Olanzapine Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olanzapine Mylan is an atypical antipsychotic that acts on dopamine and serotonin pathways to treat several psychiatric conditions. - Schizophrenia: Reduces hallucinations, delusions and thought disorder. - Bipolar I disorder (manic episodes): Helps control mood swings and acute manic symptoms. - Bipolar depression: Provides adjunctive treatment to improve depressive symptoms. - Schizoaffective disorder: Alleviates both psychotic and mood components. - Maintenance therapy: Helps prevent relapse of psychotic episodes.

Olanzapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Weight gain: Often noticeable within the first weeks of therapy. - Sedation: Drowsiness or feeling of being overly relaxed. - Dry mouth: Reduced salivation leading to a dry oral cavity. - Constipation: Slowed gastrointestinal motility. - Elevated triglycerides: Increases in blood lipid levels. - Increased appetite: May contribute to weight gain.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: Potentially life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: Involuntary, repetitive movements, especially of the face. - Hyperglycaemia/diabetes mellitus: Significant rise in blood glucose levels. - Seizures: May provoke convulsive episodes in susceptible individuals. - Agranulocytosis: Marked reduction in white‑blood cell count. - Severe hypotension: Marked drop in blood pressure, especially when standing.

When prescribing Olanzapine Mylan, clinicians should consider several safety aspects. - Monitor metabolic parameters: Regularly check weight, fasting glucose and lipid profile. - Assess for cardiovascular risk: Evaluate blood pressure and heart rate regularly. - Screen for movement disorders: Observe for early signs of tardive dyskinesia. - Use caution in hepatic impairment: Dose adjustments may be required. - Avoid abrupt discontinuation: Gradual tapering reduces relapse risk. - Store at below 25°C: Keep in the original container, protect from moisture and light.

Olanzapine can interact with a variety of medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): Increase olanzapine plasma levels. - CNS depressants (e.g., benzodiazepines, opio opio");

Moderate 

Sorry ");